IP Library › Granted Patent US 9,546,180
Granted Patent B2
US 9,546,180 · App. 14/297,526 · Granted Jan 17, 2017

Heterocyclic compounds and uses thereof

Inventors: Alfredo C. Castro (Woburn, MA); Catherine A. Evans (Somerville, MA); Somarajannair Janardanannair (Woburn, MA); Andre Lescarbeau (Somerville, MA); Tao Liu (Ashland, MA); Daniel A. Snyder (Somerville, MA); Martin R. Tremblay (Melrose, MA); Pingda Ren (San Diego, CA); Yi Liu (San Diego, CA); Liansheng Li (San Diego, CA); Katrina Chan (Fremont, CA)
Assignee: Infinity Pharmaceuticals, Inc.
C07D495/04A61K31/506A61K31/517A61K31/5377A61K45/06C07D401/12C07D401/14C07D403/12C07D403/14C07D405/14C07D411/14C07D413/14C07D417/14C07D471/04C07D487/04C07D513/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,546,180
App. No.
14/297,526
Granted
Jan 17, 2017
Kind
B2
Abstract

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.

Claims (83)

1. A compound of Formula (I):

or an enantiomer, a mixture of enantiomers, or a mixture of two or more diastereomers thereof, or a pharmaceutically acceptable form thereof, wherein

W b 1 and W b 2 are each independently CR 6 , S, O, N or NR 14 , wherein at least one of W b 1 and W b 2 is CR 6 , N or NR 14 ;

W b 5 is CR 8 , CHR 8 , or N;

p is 1;

B is hydrogen, alkenyl, alkynyl, amino, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is substituted with 0-4 R 2 ;

each R 2 is independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea or carbonate;

X is absent or is (CH(R 9 )) z —;

Y is absent, —O—, —S—, —S(═O)—, —S(═O) 2 —, —N(R 9 )—, —C(═O)—(CHR 9 ) z —, —C(═O)—, —N(R 9 )—C(═O)NH—, or —N(R 9 )C(R 9 ) 2 —;

each z is independently an integer of 1, 2, 3, or 4;

R 3 is a 6-membered heteroaryl or 6-membered heterocyclyl; wherein each of the above substituents is substituted with 0, 1, 2, or 3 R 13 ;

each R 6 is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, fluoroalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfinyl, sulfonyl, sulfoxide, sulfone, sulfonamido, halo, cyano, heteroaryl, aryl, hydroxyl, or nitro;

R 8 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, alkoxy, amino, acyl, acyloxy, sulfonamido, halo, cyano, hydroxyl, or nitro;

each R 9 is independently hydrogen, alkyl, cycloalkyl, heterocyclyl or heteroalkyl;

W d is

A is N or CR 19 ;

R 10 , R 11 , R 12 , R 13 , and R 19 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocyclyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, haloalkyl, cyano, hydroxyl, nitro, phosphate, urea, carbonate, oxo, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety; and

each R 14 is independently hydrogen, alkyl, cycloalkyl, heterocyclyl or heteroalkyl.

2. The compound of claim 1 , wherein the compound of Formula (I) has a structure of Formula (II):

3. The compound of claim 2 , wherein the compound of Formula (I) has a structure of Formula (IIb):

4. The compound of claim 2 , wherein the compound of Formula (I) has a structure of Formula (III):

5. The compound of claim 4 , wherein the compound of Formula (I) has a structure of Formula (IIIb-1):

6. The compound of claim 5 , wherein R 3 is a 6-membered heteroaryl substituted with 1 R 13 , B is aryl, R 8 is hydrogen, R 9 is alkyl, and R 10 , R 11 , and R 12 are independently hydrogen, amino, and cyano.

7. The compound of claim 6 , wherein R 3 is pyridyl substituted with alkoxy.

8. The compound of claim 6 , wherein B is phenyl substituted with 0 occurrences of R 2 .

9. The compound of claim 6 , wherein R 9 is methyl.

10. The compound of claim 6 , wherein R 10 is amino, R 11 is cyano, and R 12 is hydrogen.

11. The compound of claim 1 , wherein R 3 is 6-membered heteroaryl substituted with 1, 2 or 3 R 13 .

12. The compound of claim 1 , wherein R 3 is pyridyl substituted with 1, 2 or 3 R 13 .

13. The compound of claim 1 , wherein A is N.

14. The compound of claim 1 , wherein W d is:

15. The compound of claim 14 , wherein W d is

16. The compound of claim 1 , wherein B is heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is substituted with 0-4 R 2 .

17. The compound of claim 16 , wherein B is aryl substituted with 0-4 occurrences of R 2 .

18. The compound of claim 17 , wherein B is phenyl substituted with 0 occurrences of R 2 .

19. The compound of claim 1 , wherein R 8 is hydrogen.

20. The compound of claim 1 , wherein R 9 is methyl.

21. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable form thereof.

22. A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable excipients.

23. A compound of Formula (I):

or an enantiomer, a mixture of enantiomers, or a mixture of two or more diastereomers thereof, or a pharmaceutically acceptable form thereof, wherein

W b 1 and W b 2 are each independently CR 6 , S, O, N or NR 14 , wherein at least one of W b 1 and W b 2 is CR 6 , N or NR 14 ;

W b 5 is CR 8 , CHR 8 , or N;

p is 1;

B is hydrogen, alkyl, alkenyl, alkynyl, amino, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is substituted with 0-4 R 2 ;

each R 2 is independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea or carbonate;

X is absent or is (CH(R 9 )) z —;

Y is absent, —O—, —S—, —S(═O)—, —S(═O) 2 —, —N(R 9 )—, —C(═O)—(CHR 9 ) z —, —C(═O)—, —N(R 9 )—C(═O)NH—, or —N(R 9 )C(R 9 ) 2 —;

each z is independently an integer of 1, 2, 3, or 4;

R 3 is aryl, 9-membered heteroaryl, or 10-membered heteroaryl, or R 3 is a heteroatom selected from N, S, and O, wherein the heteroatom has a covalent bond, either directly or through a C 1 -C 6 alkyl group, to an aryl, heteroaryl or heterocyclyl, wherein each of the above substituents is substituted with 0, 1, 2, or 3 R 13 ;

each R 6 is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, fluoroalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfinyl, sulfonyl, sulfoxide, sulfone, sulfonamido, halo, cyano, heteroaryl, aryl, hydroxyl, or nitro;

R 8 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, alkoxy, amino, acyl, acyloxy, sulfonamido, halo, cyano, hydroxyl, or nitro;

each R 9 is independently hydrogen, alkyl, cycloalkyl, heterocyclyl or heteroalkyl;

W d is

A is N or CR 19 ;

R 10 , R 11 , R 12 , R 13 , and R 19 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocyclyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, haloalkyl, cyano, hydroxyl, nitro, phosphate, urea, carbonate, oxo, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety; and

each R 14 is independently hydrogen, alkyl, cycloalkyl, heterocyclyl or heteroalkyl.

24. The compound of claim 23 , wherein the compound of Formula (I) has a structure of Formula (IIb):

25. The compound of claim 23 , wherein R 3 is a fused 5/6-bicyclic heteroaryl or fused 6/6-bicyclic heteroaryl, wherein each of the above substituents is substituted with 0, 1, 2, or 3 R 13 .

26. The compound of claim 23 , wherein the compound is:

or a pharmaceutically acceptable form thereof.

27. A pharmaceutical composition comprising a compound according to claim 23 and one or more pharmaceutically acceptable excipients.

28. A compound of Formula (I):

or an enantiomer, a mixture of enantiomers, or a mixture of two or more diastereomers thereof, or a pharmaceutically acceptable form thereof, wherein

W b 1 and W b 2 are each independently CR 6 , S, O, N or NR 14 , wherein at least one of W b 1 and W b 2 is CR 6 , N or NR 14 ;

W b 5 is CR 8 , CHR 8 , or N;

p is 1;

B is hydrogen, alkyl, alkenyl, alkynyl, amino, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is substituted with 0-4 R 2 ;

each R 2 is independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea or carbonate;

X is absent or is —(CH(R 9 )) z —;

Y is absent, —O—, —S—, —S(═O)—, —S(═O) 2 —, —N(R 9 )—, —C(═O)—(CHR 9 ) z —, —C(═O)—, —N(R 9 )—C(═O)NH—, or —N(R 9 )C(R 9 ) 2 —;

each z is independently an integer of 1, 2, 3, or 4;

R 3 is 5-membered heteroaryl or 5-membered heterocyclyl, wherein each of the above substituents is substituted with 0, 1, 2, or 3 R 13 ;

each R 6 is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, fluoroalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfinyl, sulfonyl, sulfoxide, sulfone, sulfonamido, halo, cyano, heteroaryl, aryl, hydroxyl, or nitro;

R 8 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, alkoxy, amino, acyl, acyloxy, sulfonamido, halo, cyano, hydroxyl, or nitro;

each R 9 is independently hydrogen, alkyl, cycloalkyl, heterocyclyl or heteroalkyl;

W d is

A is N or CR 19 ;

R 10 , R 11 , R 12 , R 13 , and R 19 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocyclyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, haloalkyl, cyano, hydroxyl, nitro, phosphate, urea, carbonate, oxo, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety; and

each R 14 is independently hydrogen, alkyl, cycloalkyl, heterocyclyl or heteroalkyl, and

wherein the compound of Formula (I) is not one of the following compounds:

29. The compound of claim 28 , wherein the compound is:

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2014
From: CASTRO, ALFREDO C.; EVANS, CATHERINE A.; JANARDANANNAIR, SOMARAJANNAIR; LESCARBEAU, ANDRE; LIU, TAO; SNYDER, DANIEL A.; TREMBLAY, MARTIN R.
To: INFINITY PHARMACEUTICALS, INC.
Reel/Frame 033762/0285 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2014
From: REN, PINGDA; LIU, YI; LI, LIANSHENG; CHAN, KATRINA
To: INTELLIKINE LLC
Reel/Frame 033762/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2014
From: INTELLIKINE LLC
To: INFINITY PHARMACEUTICALS, INC.
Reel/Frame 033762/0410 →
Continuity (7)
Continuation 13552516 · Jul 18, 2012
Provisional Application 61528585 · Aug 29, 2011
Provisional Application 61547343 · Oct 14, 2011
Provisional Application 61562278 · Nov 21, 2011
Provisional Application 61595947 · Feb 7, 2012
Provisional Application 61645982 · May 11, 2012
Related Publication 20140288048A1 · Sep 25, 2014